Cyclodiode laser is an effective alternative to lensectomy in acute angle closure

Article

Using a cyclodiode laser to manage acute angle closure is a safe and effective alternative to emergency lensectomy or trabeculectomy

Using a cyclodiode laser to manage acute angle closure is a safe and effective alternative to emergency lensectomy or trabeculectomy, claims a study in the journal Eye.

Dr A. Manna et al., Birmingham Midland Eye Centre, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK, conducted a retrospective case series on five patients with acute angle closure refractory to medical and laser treatment.

All participants underwent cyclodiode laser treatment. The team recorded each patient's demographic information, symptoms, medical and surgical treatment, visual outcomes and intraocular pressure (IOP).

Sufficient IOP control was not achieved with conventional management such as topical and systemic medical treatment, laser iridotomy and laser iridoplasty. Within 2 to 23 days of presentation of acute angle closure, emergency cyclodiode laser treatment was completed.

Lensectomy was performed in all patients at a later date, with final visual acuity of 6/12 or better with well-maintained IOPs. Just one patient required topical treatment and one patient developed persistent low-grade anterior uveitis.

Cyclodiode laser treatment is a successful alternative to managing acute angle closure for patients who do not respond to other treatments.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.